Video

Dr. Baselga Discusses Upcoming BOLERO-3 Data

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

In addition to the data regarding everolimus in ER-positive tumor, there is also evidence demonstrating that everolimus can enhance the effect of trastuzumab in patients with HER2-positive disease.

Data from the BOLERO-3 trial will be released soon, Baselga says. He is hopeful that the data will show benefit and provide another option for patients with HER2-positive disease.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School